BRAF and melanoma: However, with the emergence of small molecule drugs for melanoma targeting BRAF mutations, which are present in over half of melanoma cases (Pollock et al., 2003), the clinical relevance of a cell line with wild-type BRAF was brought into question as the mutational landscape of the B16 line is unlike that seen in human melanoma (Zhong et al., 2020) particularly in the context of common driver mutations.